The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. The Company expects to finalize the agreement with the research institute and commence studies by Fall 2021. The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. CHARLOTTE, N.C.–(BUSINESS

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Cannabis Law Report

AUGUST 13, 2021

Instead, it is hypothesised that SalA indirectly influences the cannabinoid system, as well as being an allosteric modulator of the µ opioid receptor. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Veriheal

SEPTEMBER 18, 2020

Research Team to Study the Impact of CBD on Spinal Injury Pain. million of NWS Health funding for their Cannabinoid Therapeutics and Brain and Mind Centre to see if cannabidiol can be that effective treatment for spinal cord injury. Dr. Carins is a postdoctoral researcher who completed her Ph.D. Along with the $1.7

Treatment 97

Treatment Chronic Pain Research and Development CBD 97

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. Strict cash management controls are in operation across all areas of expenditure, whereby all budgeted central costs have been reviewed with measures agreed to reduce these wherever possible, in order to maximise the Group’s financial resources available for its drug development programmes.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

LifeCannMD

FEBRUARY 27, 2024

Inflammation in the brain is thought to contribute to the development and persistence of seizures. The most compelling evidence of the effectiveness of Medical Marijuana in treating epilepsy comes from clinical trials. Medical Marijuana has been shown to have anti-inflammatory properties.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

Cannabis Law Report

SEPTEMBER 2, 2022

LOBEF signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 Funding for psychedelics research and clinical trials is certainly here to stay. Psychedelics biopharma company Lobe Sciences Ltd.

Clinical Trials 52

Clinical Trials Research and Development Cannabinoids Medicine 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. 561-627-9455.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. Junk’ cannabis ‘ill-suited for clinical trials’.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. Preliminary Research on CBD Oil. CBD is the most abundant active ingredient within the CBD oil.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. Preliminary Research on CBD Oil. CBD is the most abundant active ingredient within the CBD oil.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well. Approved Cannabinoid-Based Medications.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

The Cannigma

APRIL 12, 2023

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. What this means for CBN research These results are, in a word, impressive. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated. These marketing claims are abundant, yet most of the evidence is anecdotal.

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. The Group currently has four drug development programmes running in parallel.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

AUGUST 10, 2021

Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well. Approved Cannabinoid-Based Medications.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

MMJ Recs

DECEMBER 28, 2023

In this article, we’ll talk about a few of the most common conditions for which medical marijuana is prescribed, exploring the growing body of research and real-world experiences that contribute to its acceptance as a viable therapeutic option. CBD, a non-psychoactive cannabinoid, has gained attention for its anti-anxiety effects.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Greencamp

AUGUST 16, 2018

In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Exploring the available research on ALS and cannabinoids. As few as 10% of ALS patients live longer than 10 years after being diagnosed.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

The Cannigma

DECEMBER 14, 2021

Hexahydrocannabinol (HHC), which was patented in the late 1940s as a “therapeutic substance having marihuana activity,” is a cannabinoid that’s growing in popularity and availability. HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant. HHC metabolism.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

Cannabis Law Report

MARCH 18, 2020

The company, a leader in hemp-derived CBD extract products, has created an internal research and development division led by a former healthcare executive to focus on the science of hemp-derived phytocannabinoids, terpenes and flavonoid compounds. Charlotte’s Web Holdings, Inc. CW Labs and have an additional office in Boulder, Colo.

Clinical Trials 59

Clinical Trials Research and Development Terpenes Hemp 59

CannaMD

MAY 25, 2021

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. At the four week mark and beyond, however, this trend reversed, resulting in an increase in new bone development.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Cannabis Law Report

JANUARY 11, 2022

DENVER–(BUSINESS WIRE)– Ripple , Colorado’s trusted cannabis edibles brand and pioneer of fast-acting and clinically proven technology, is leading the way in cannabis wellness with new Ripple Sleep QuickDissolves and Ripple Sleep QuickGummies. Our mission is to improve people’s lives through cannabinoids.

THC 52

THC Clinical Trials Research and Development Sleep 52

The Cannigma

JUNE 23, 2022

While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. What is the difference between CBG and CBGa? What does CBGA do?

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113